A 28-year-old woman with HIV-1 infection (CD4 count 180 cells/μL) who is currently on dolutegravir + tenofovir + lamivudine for 6 months presents with virological failure (viral load 45,000 copies/mL). Genotypic testing shows M184V mutation (lamivudine resistance) and no integrase inhibitor resistance mutations. What is the preferred next-line regimen?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.